(Q38475230)

3 September 2017

title

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients (English)

1 reference

3 September 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Joon Ho Moon

1

1 reference

3 September 2017

Sang Kyun Sohn

2

1 reference

3 September 2017

Shi Nae Kim

3

1 reference

3 September 2017

Seon Yang Park

4

1 reference

3 September 2017

Sung Soo Yoon

5

1 reference

3 September 2017

In Ho Kim

6

1 reference

3 September 2017

Hyeoung Joon Kim

7

1 reference

3 September 2017

Yeo Kyeoung Kim

8

1 reference

3 September 2017

Yoo Hong Min

9

1 reference

3 September 2017

June Won Cheong

10

1 reference

3 September 2017

Jin Seok Kim

11

1 reference

3 September 2017

Chul Won Jung

12

1 reference

3 September 2017

Dong Hwan Kim

13

1 reference

3 September 2017

publication date

7 April 2011

1 reference

3 September 2017

1 reference

3 September 2017

volume

29

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

1179-1185

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Optimizing treatment of chronic myeloid leukemia: a rational approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Facilitating oral chemotherapy treatment and compliance through patient/family-focused education

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Patient adherence and persistence with oral anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Compliance with oral drug therapy in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9926-8

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21472487

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21472487

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-011-9926-8

1 reference

Dimensions Publication ID

3 September 2017

1002505678

0 references

Fatcat ID

release_666x7ikimnhdbb6wgk2udz75ou

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/666x7ikimnhdbb6wgk2udz75ou

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference